Wednesday
May 14, 2025
10:00 AM ET
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Thursday
May 1, 2025
6:30 AM ET
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
Thursday
April 17, 2025
7:00 AM ET
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
Thursday
February 13, 2025
6:31 AM ET
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Thursday
February 6, 2025
7:00 AM ET
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Monday
January 13, 2025
7:00 AM ET
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
Wednesday
January 8, 2025
7:00 AM ET
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
Wednesday
December 18, 2024
7:00 AM ET
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Sunday
December 8, 2024
12:40 PM ET
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat